ImmunityBio.
biotech company
- Reports this week
- 0
- Active events
- 1
- Connections
- 44
What's happening
Active this week
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
Tariffs and onshoring trends are benefiting AI stocks, while a company acquisition enhances its liver disease portfolio, aided by a breakthrough designation.Some support7 reports4 developments inside
-
ImmunityBio presented Phase 3 clinical trial data, leading UBS to upgrade its rating from Neutral to Buy.Some support1 report
-
ImmunityBio received Expanded Access authorization from the FDA on June 25, 2025.Speculative1 report
-
ImmunityBio received prior approval in the U.S. on July 8, 2025, and Patrick Soon-Shiong was noted as Founder and Executive Chairman.Speculative1 report
-
ImmunityBio initiated Phase 1 trials for NSCLC in US sites, while the FDA remained supportive of new data and the company sought guideline expansion from NCCN.Some support1 report
-
ImmunityBio's offering requires filing with the SEC, with the associated book-running office located in Minneapolis.Some support2 reports
-
The FDA authorized an Expanded Access Program for ANKTIVA, the lead therapy of ImmunityBio, on July 31, 2025.Some support1 report
-
ImmunityBio received FDA approval for its ANKTIVA immunotherapy drug on August 18, 2025, with treatment administered in Houston.Some support3 reports1 development inside
-
ImmunityBio met with the FDA division on August 5, 2025, to present data regarding its ANKTIVA drug used in an NCI cancer prevention trial.Some support1 report
-
ImmunityBio's findings regarding GBM statistics were related to data provided by the American Brain Tumor Association.Some support1 report1 development inside
-
ImmunityBio announced a study originating from Culver City.Some support3 reports
-
The FDA granted Expanded Access authorization for the Cancer BioShield™ platform of ImmunityBio on August 28, 2025. The company is now engaging with regulators to update clinical guidelines.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around ImmunityBio this week
News at the entities that move ImmunityBio most-
FDA StructuralFDA granted clearance for DVT treatment involving Penumbra, Inc.Moves ImmunityBio
-
Securities and Exchange Commission StructuralBWX Technologies, Inc. filed reports with the SEC as Poland seeks to enhance energy security and resiliency.Moves ImmunityBio
-
SEC StructuralIntuit filed a Form 4 with the SEC regarding insider share sales on August 30, 2026.Moves ImmunityBio
-
United Arab Emirates StructuralThe UAE University (UAEU) was established in 2026 with the vision of knowledge and innovation, founded by Sheikh Zayed bin Sultan Al Nahyan, and Zaki Anwar Nusseibeh serves as its Chancellor.Moves ImmunityBio
-
Biotech Shared contextThe biotech industry is set to develop new plastics and fuels, and Google AI is predicting future population trends.Moves ImmunityBio
-
Jefferies Financial Group Mentioned togetherJefferies Financial Group reiterated a buy rating on shares of Essentra plc, which is headquartered in the United Kingdom.Moves ImmunityBio
Connections
The 16 strongest of 44, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Patrick Soon-Shiong Structural
Patrick Soon-Shiong serves as the Founder and Executive Chairman of ImmunityBio.
-
FDA Structural
ImmunityBio's existence and market viability are structurally dependent on the FDA's regulatory approvals and guidance.
-
SEC Structural
ImmunityBio operates under the oversight and filing requirements of the U.S. Securities and Exchange Commission (SEC).
-
Securities and Exchange Commission Structural
ImmunityBio is subject to mandatory filing and disclosure requirements set by the Securities and Exchange Commission.
-
United Arab Emirates Structural
The UAE granted regulatory approval for ImmunityBio's immunotherapy drug, enabling market access.
-
Cheryl Cohen Transactional
Director Cheryl Cohen sold company shares of ImmunityBio stock.
-
Lisa McClain Transactional
Lisa McClain purchased shares of ImmunityBio.
-
Biotech Shared context
ImmunityBio's performance is described as being tied to the overall performance of the Biotech sector.
Show all 16 connections
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group issued a strong-buy upgrade recommendation for ImmunityBio.
-
National Comprehensive Cancer Network Operational
ImmunityBio actively engages the National Comprehensive Cancer Network to seek guideline expansion and operates within its clinical context.
-
MarketBeat Mentioned together
MarketBeat provides analyst ratings and coverage for ImmunityBio.
-
Culver City Shared context
ImmunityBio conducts studies and announces news while located in Culver City.
-
Editas Medicine Operational
Both healthcare companies are actively competing for investment capital.
-
UBS Transactional
ImmunityBio presented Phase 3 clinical trial data to UBS.
-
Nasdaq Shared context
ImmunityBio is listed on the Nasdaq stock exchange.
-
Dunkirk Mentioned together
No evidence found linking ImmunityBio and Dunkirk in the provided timeline.
History
Events by the month they beganOctober 2026
3 eventsSeptember 2026
1 eventJuly 2026
1 eventShow 1 earlier month
June 2026
12 events- Tariffs and onshoring trends are benefiting AI stocks, while a company acquisition enhances its liver disease portfolio, aided by a breakthrough designation.
- ImmunityBio presented Phase 3 clinical trial data, leading UBS to upgrade its rating from Neutral to Buy.
- ImmunityBio received Expanded Access authorization from the FDA on June 25, 2025.
- ImmunityBio received prior approval in the U.S. on July 8, 2025, and Patrick Soon-Shiong was noted as Founder and Executive Chairman.
- ImmunityBio initiated Phase 1 trials for NSCLC in US sites, while the FDA remained supportive of new data and the company sought guideline expansion from NCCN.
- ImmunityBio's offering requires filing with the SEC, with the associated book-running office located in Minneapolis.
- The FDA authorized an Expanded Access Program for ANKTIVA, the lead therapy of ImmunityBio, on July 31, 2025.
- ImmunityBio received FDA approval for its ANKTIVA immunotherapy drug on August 18, 2025, with treatment administered in Houston.
- ImmunityBio met with the FDA division on August 5, 2025, to present data regarding its ANKTIVA drug used in an NCI cancer prevention trial.
- ImmunityBio's findings regarding GBM statistics were related to data provided by the American Brain Tumor Association.
- ImmunityBio announced a study originating from Culver City.
- The FDA granted Expanded Access authorization for the Cancer BioShield™ platform of ImmunityBio on August 28, 2025. The company is now engaging with regulators to update clinical guidelines.